Daiichi reports Phase I data for DS-3201 in NHL

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported preliminary data from 17 evaluable patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) in an open-label, dose-escalation, Japanese Phase I trial showing that DS-3201 led to overall response rate (ORR) of 58.8%, including one complete remission and nine partial remissions, plus four cases of stable disease. The ORR was 45.5% in a subset of 11 evaluable patients with B cell lymphomas and 83.3% in a subset of six evaluable patients with T cell lymphomas.

Four dose-limiting toxicities (DLTs) were reported at the 200 and 300 mg doses of DS-3201. Specifically, there were three cases of grade 4 reductions in platelet counts at both doses and one case of grade 3 anemia requiring transfusion at the 300 mg dose. Data were presented at the American Society of Hematology meeting in Atlanta in December...